Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.72 USD
Change Today -0.015 / -2.04%
Volume 122.0K
RNN On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 12:23 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (RNN) Snapshot

Open
$0.73
Previous Close
$0.74
Day High
$0.74
Day Low
$0.72
52 Week High
04/2/14 - $1.29
52 Week Low
11/17/14 - $0.65
Market Cap
129.0M
Average Volume 10 Days
648.0K
EPS TTM
$-0.11
Shares Outstanding
179.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REXAHN PHARMACEUTICALS INC (RNN)

Related News

No related news articles were found.

rexahn pharmaceuticals inc (RNN) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (RNN) Details

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.

22 Employees
Last Reported Date: 03/16/15

rexahn pharmaceuticals inc (RNN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $380.8K
President and Chief Operating Officer
Total Annual Compensation: $268.8K
Founder, Chairman of the Board and Chief Scie...
Total Annual Compensation: $319.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.1K
Compensation as of Fiscal Year 2013.

rexahn pharmaceuticals inc (RNN) Key Developments

Rexahn Pharmaceuticals, Inc. Announces an Update of Three Clinical Development Programs and Financial Results for the Year Ended December 31, 2014

Rexahn Pharmaceuticals, Inc. announced an update of three clinical development programs and financial results for the year ended December 31, 2014. For the year, the company reported loss from operations of $13.3 million against $8.0 million a year ago. Net loss was $18.5 million, or $0.11 per share compared to $9.5 million, or $0.07 per share for the year ended December 31, 2013. Included in net loss for the year ended December 31, 2014 and 2013 is an unrealized loss on the fair value of warrants of $5.2 million and $1.4 million, respectively. Company's cash and investments totaled $32.7 million as of December 31, 2014, compared to $19.0 million as of December 31, 2013. The increase of $13.7 million was primarily due to $18.6 million in proceeds received from registered direct public offering, and $6.2 million received from the exercise of stock options and warrants, offset by $11.1 million from net cash used in operating activities. The company announced pipeline update: Supinoxin™ (RX-5902): An ongoing Phase I dose-escalation clinical trial of Supinoxin is designed to evaluate the safety, tolerability, dose-limiting toxicities and MTD in cancer patients with solid tumors. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. Patients in seven dose groups (25, 50, 100, 150, 225, 300 and 425 mg) have been enrolled, and the MTD has not yet been reached. Depending upon the number of dose groups needed to determine the MTD, Rexahn expects to complete this trial in the first half of 2015. Supinoxin continues to be safe and well tolerated, requiring higher dose levels than expected to be tested to achieve the MTD. RX-3117: An ongoing Phase Ib dose-escalation clinical trial of RX-3117 is designed to evaluate the safety, tolerability, dose-limiting toxicities and MTD in cancer patients with solid tumors. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of RX-3117. Patient enrollment has been completed in eight dose groups (30, 60, 100, 150, 200, 500, 1,000 and 1,500 mg). The MTD of RX-3117 has not yet been achieved. The Company expects to complete this trial in the first half of 2015. RX-3117 continues to be safe and well tolerated, requiring higher dose levels than expected to be tested to achieve the MTD. To date, no dose-limiting toxicities have been associated with RX-3117 treatment. Archexin®: The Phase IIa proof-of-concept clinical trial of Archexin in metastatic renal cell carcinoma (RCC) patients is ongoing. The first stage of this study is dose ranging, with up to three dose groups with three RCC patients each, to determine the MTD of Archexin in combination with everolimus, an FDA approved drug for the treatment of RCC. Patient enrollment is ongoing. Rexahn has orphan drug designation for this indication.

Rexahn Pharmaceuticals, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 11:15 AM

Rexahn Pharmaceuticals, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 11:15 AM. Venue: Grand Hyatt Hotel, Tokyo, Japan. Speakers: Vikas Sharma, Director of Business Development.

Rexahn Pharmaceuticals, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 09:15 AM

Rexahn Pharmaceuticals, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 09:15 AM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNN:US $0.72 USD -0.015

RNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RNN.
View Industry Companies
 

Industry Analysis

RNN

Industry Average

Valuation RNN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit www.rexahn.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.